Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the involvement of small airways in asthma, as
determined by bronchial challenges, CT-scanning, and cellular markers of inflammation.
Ciclesonide will be inhaled at one dose level once daily. The study duration consists of a
baseline period (2 to 3 weeks) and a treatment period (5 to 6 weeks). The study will provide
further data on safety and tolerability of ciclesonide.